Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation
Departments of 1 Medicine, 2 Pharmacology and Therapeutics, and 3 Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada; and 4 Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico Submitted 15 September 2007 ; accepted in final form 6 February 2008 In...
Gespeichert in:
Veröffentlicht in: | American journal of physiology. Heart and circulatory physiology 2008-04, Vol.294 (4), p.H1724-H1735 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | H1735 |
---|---|
container_issue | 4 |
container_start_page | H1724 |
container_title | American journal of physiology. Heart and circulatory physiology |
container_volume | 294 |
creator | Mink, Steven N Kasian, Krika Santos Martinez, Luis E Jacobs, Hans Bose, Ratna Cheng, Zhao-Qin Light, R. Bruce |
description | Departments of 1 Medicine, 2 Pharmacology and Therapeutics, and 3 Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada; and 4 Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Submitted 15 September 2007
; accepted in final form 6 February 2008
In septic shock, systemic vasodilation and myocardial depression contribute to the systemic hypotension observed. Both components can be attributed to the effects of mediators that are released as part of the inflammatory response. We previously found that lysozyme (Lzm-S), released from leukocytes, contributed to the myocardial depression that develops in a canine model of septic shock. Lzm-S binds to the endocardial endothelium, resulting in the production of nitric oxide (NO), which, in turn, activates the myocardial soluble guanylate cyclase (sGC) pathway. In the present study, we determined whether Lzm-S might also play a role in the systemic vasodilation that occurs in septic shock. In a phenylephrine-contracted canine carotid artery ring preparation, we found that both canine and human Lzm-S, at concentrations similar to those found in sepsis, produced vasorelaxation. This decrease in force could not be prevented by inhibitors of NO synthase, prostaglandin synthesis, or potassium channel inhibitors and was not dependent on the presence of the vascular endothelium. However, inhibitors of the sGC pathway prevented the vasodilatory activity of Lzm-S. In addition, Aspergillus niger catalase, which breaks down H 2 O 2 , as well as hydroxyl radical scavengers, which included hydroquinone and mannitol, prevented the effect of Lzm-S. Electrochemical sensors corroborated that Lzm-S caused H 2 O 2 release from the carotid artery preparation. In conclusion, these results support the notion that when Lzm-S interacts with the arterial vasculature, this interaction results in the formation of H 2 O 2 , which, in turn, activates the sGC pathway to cause relaxation. Lzm-S may contribute to the vasodilation that occurs in septic shock.
reactive oxygen species; catalase; compound I; hydroxyl radical; septic shock; hypotension
Address for reprint requests and other correspondence: S. N. Mink, Health Sciences Centre, GF-221, 820 Sherbrook St., Winnipeg, Manitoba, Canada R3A 1R9 (e-mail: minksn{at}cc.umanitoba.ca ) |
doi_str_mv | 10.1152/ajpheart.01072.2007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_229675813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1460409241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-752ea63a2b08bd4c68cf0ca41c7322bab4c8b558514047cc1d90eb0c46e971033</originalsourceid><addsrcrecordid>eNp1kF2L1DAYhYMo7rj6CwQJXtvZfDYtXsniusKAN-t1SNO3bYZOU5PU3frrzeyMqzdC4L3IeQ6HB6G3lGwplezK7OcBTEhbQoliW0aIeoY2-YcVVPL6OdoQXvKipFxeoFcx7gkhUpX8JbqgFSu5omKD4m6N_td6gA_Y4AO0ziQfsO9whDm6iNNgEp6DbxcLEf800bduNMn5CTcrHtY2-B4mPEPwD64FHF0_mdFNPXYTNvmFBMGZMXfAbMIj-Rq96MwY4c35XqLvN5_vrm-L3bcvX68_7QorGEuFkgxMyQ1rSNW0wpaV7Yg1glrFGWtMI2zVSFlJKohQ1tK2JtAQK0qoFSWcX6L3p968_8cCMem9X0KeFzVjdalkRY8hfgrZ4GMM0Ok5uIMJq6ZEHz3rP571o2d99Jypd-fqpcnW_jJnsTnw8RQYXD_cuwB6Htbo_Oj7Vd8s43gHD-mpmtVCC31LFRN6brtMX_2fftrzD8V_Axkko48</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229675813</pqid></control><display><type>article</type><title>Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation</title><source>MEDLINE</source><source>American Physiological Society</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Mink, Steven N ; Kasian, Krika ; Santos Martinez, Luis E ; Jacobs, Hans ; Bose, Ratna ; Cheng, Zhao-Qin ; Light, R. Bruce</creator><creatorcontrib>Mink, Steven N ; Kasian, Krika ; Santos Martinez, Luis E ; Jacobs, Hans ; Bose, Ratna ; Cheng, Zhao-Qin ; Light, R. Bruce</creatorcontrib><description>Departments of 1 Medicine, 2 Pharmacology and Therapeutics, and 3 Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada; and 4 Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Submitted 15 September 2007
; accepted in final form 6 February 2008
In septic shock, systemic vasodilation and myocardial depression contribute to the systemic hypotension observed. Both components can be attributed to the effects of mediators that are released as part of the inflammatory response. We previously found that lysozyme (Lzm-S), released from leukocytes, contributed to the myocardial depression that develops in a canine model of septic shock. Lzm-S binds to the endocardial endothelium, resulting in the production of nitric oxide (NO), which, in turn, activates the myocardial soluble guanylate cyclase (sGC) pathway. In the present study, we determined whether Lzm-S might also play a role in the systemic vasodilation that occurs in septic shock. In a phenylephrine-contracted canine carotid artery ring preparation, we found that both canine and human Lzm-S, at concentrations similar to those found in sepsis, produced vasorelaxation. This decrease in force could not be prevented by inhibitors of NO synthase, prostaglandin synthesis, or potassium channel inhibitors and was not dependent on the presence of the vascular endothelium. However, inhibitors of the sGC pathway prevented the vasodilatory activity of Lzm-S. In addition, Aspergillus niger catalase, which breaks down H 2 O 2 , as well as hydroxyl radical scavengers, which included hydroquinone and mannitol, prevented the effect of Lzm-S. Electrochemical sensors corroborated that Lzm-S caused H 2 O 2 release from the carotid artery preparation. In conclusion, these results support the notion that when Lzm-S interacts with the arterial vasculature, this interaction results in the formation of H 2 O 2 , which, in turn, activates the sGC pathway to cause relaxation. Lzm-S may contribute to the vasodilation that occurs in septic shock.
reactive oxygen species; catalase; compound I; hydroxyl radical; septic shock; hypotension
Address for reprint requests and other correspondence: S. N. Mink, Health Sciences Centre, GF-221, 820 Sherbrook St., Winnipeg, Manitoba, Canada R3A 1R9 (e-mail: minksn{at}cc.umanitoba.ca )</description><identifier>ISSN: 0363-6135</identifier><identifier>EISSN: 1522-1539</identifier><identifier>DOI: 10.1152/ajpheart.01072.2007</identifier><identifier>PMID: 18263714</identifier><identifier>CODEN: AJPPDI</identifier><language>eng</language><publisher>United States: American Physiological Society</publisher><subject><![CDATA[Aminoquinolines - pharmacology ; Animals ; Blood vessels ; Carotid Artery, Internal - drug effects ; Carotid Artery, Internal - enzymology ; Carotid Artery, Internal - metabolism ; Catalase - metabolism ; Cells ; Cyclic GMP - analogs & derivatives ; Cyclic GMP - metabolism ; Cyclic GMP - pharmacology ; Cyclic GMP-Dependent Protein Kinases - antagonists & inhibitors ; Cyclic GMP-Dependent Protein Kinases - metabolism ; Cyclooxygenase Inhibitors - pharmacology ; Dogs ; Dose-Response Relationship, Drug ; Enzyme Inhibitors - pharmacology ; Enzymes ; Ethanol - pharmacology ; Free Radical Scavengers - pharmacology ; Guanylate Cyclase - antagonists & inhibitors ; Guanylate Cyclase - metabolism ; Humans ; Hydrogen Peroxide - metabolism ; Hydroquinones - pharmacology ; In Vitro Techniques ; Indomethacin - pharmacology ; Mannitol - pharmacology ; Mesenteric Artery, Superior - drug effects ; Mesenteric Artery, Superior - enzymology ; Mesenteric Artery, Superior - metabolism ; Methylene Blue - pharmacology ; Muramidase - antagonists & inhibitors ; Muramidase - metabolism ; Nitric oxide ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - antagonists & inhibitors ; Nitric Oxide Synthase - metabolism ; omega-N-Methylarginine - pharmacology ; Oxadiazoles - pharmacology ; Phenylephrine - pharmacology ; Prostaglandins - metabolism ; Protein Kinase Inhibitors - pharmacology ; Quinoxalines - pharmacology ; Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors ; Receptors, Cytoplasmic and Nuclear - metabolism ; Sepsis - metabolism ; Sepsis - physiopathology ; Signal transduction ; Signal Transduction - drug effects ; Soluble Guanylyl Cyclase ; Studies ; Thionucleotides - pharmacology ; Time Factors ; Vasoconstrictor Agents - pharmacology ; Vasodilation - drug effects]]></subject><ispartof>American journal of physiology. Heart and circulatory physiology, 2008-04, Vol.294 (4), p.H1724-H1735</ispartof><rights>Copyright American Physiological Society Apr 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-752ea63a2b08bd4c68cf0ca41c7322bab4c8b558514047cc1d90eb0c46e971033</citedby><cites>FETCH-LOGICAL-c422t-752ea63a2b08bd4c68cf0ca41c7322bab4c8b558514047cc1d90eb0c46e971033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3039,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18263714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mink, Steven N</creatorcontrib><creatorcontrib>Kasian, Krika</creatorcontrib><creatorcontrib>Santos Martinez, Luis E</creatorcontrib><creatorcontrib>Jacobs, Hans</creatorcontrib><creatorcontrib>Bose, Ratna</creatorcontrib><creatorcontrib>Cheng, Zhao-Qin</creatorcontrib><creatorcontrib>Light, R. Bruce</creatorcontrib><title>Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation</title><title>American journal of physiology. Heart and circulatory physiology</title><addtitle>Am J Physiol Heart Circ Physiol</addtitle><description>Departments of 1 Medicine, 2 Pharmacology and Therapeutics, and 3 Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada; and 4 Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Submitted 15 September 2007
; accepted in final form 6 February 2008
In septic shock, systemic vasodilation and myocardial depression contribute to the systemic hypotension observed. Both components can be attributed to the effects of mediators that are released as part of the inflammatory response. We previously found that lysozyme (Lzm-S), released from leukocytes, contributed to the myocardial depression that develops in a canine model of septic shock. Lzm-S binds to the endocardial endothelium, resulting in the production of nitric oxide (NO), which, in turn, activates the myocardial soluble guanylate cyclase (sGC) pathway. In the present study, we determined whether Lzm-S might also play a role in the systemic vasodilation that occurs in septic shock. In a phenylephrine-contracted canine carotid artery ring preparation, we found that both canine and human Lzm-S, at concentrations similar to those found in sepsis, produced vasorelaxation. This decrease in force could not be prevented by inhibitors of NO synthase, prostaglandin synthesis, or potassium channel inhibitors and was not dependent on the presence of the vascular endothelium. However, inhibitors of the sGC pathway prevented the vasodilatory activity of Lzm-S. In addition, Aspergillus niger catalase, which breaks down H 2 O 2 , as well as hydroxyl radical scavengers, which included hydroquinone and mannitol, prevented the effect of Lzm-S. Electrochemical sensors corroborated that Lzm-S caused H 2 O 2 release from the carotid artery preparation. In conclusion, these results support the notion that when Lzm-S interacts with the arterial vasculature, this interaction results in the formation of H 2 O 2 , which, in turn, activates the sGC pathway to cause relaxation. Lzm-S may contribute to the vasodilation that occurs in septic shock.
reactive oxygen species; catalase; compound I; hydroxyl radical; septic shock; hypotension
Address for reprint requests and other correspondence: S. N. Mink, Health Sciences Centre, GF-221, 820 Sherbrook St., Winnipeg, Manitoba, Canada R3A 1R9 (e-mail: minksn{at}cc.umanitoba.ca )</description><subject>Aminoquinolines - pharmacology</subject><subject>Animals</subject><subject>Blood vessels</subject><subject>Carotid Artery, Internal - drug effects</subject><subject>Carotid Artery, Internal - enzymology</subject><subject>Carotid Artery, Internal - metabolism</subject><subject>Catalase - metabolism</subject><subject>Cells</subject><subject>Cyclic GMP - analogs & derivatives</subject><subject>Cyclic GMP - metabolism</subject><subject>Cyclic GMP - pharmacology</subject><subject>Cyclic GMP-Dependent Protein Kinases - antagonists & inhibitors</subject><subject>Cyclic GMP-Dependent Protein Kinases - metabolism</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Dogs</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzymes</subject><subject>Ethanol - pharmacology</subject><subject>Free Radical Scavengers - pharmacology</subject><subject>Guanylate Cyclase - antagonists & inhibitors</subject><subject>Guanylate Cyclase - metabolism</subject><subject>Humans</subject><subject>Hydrogen Peroxide - metabolism</subject><subject>Hydroquinones - pharmacology</subject><subject>In Vitro Techniques</subject><subject>Indomethacin - pharmacology</subject><subject>Mannitol - pharmacology</subject><subject>Mesenteric Artery, Superior - drug effects</subject><subject>Mesenteric Artery, Superior - enzymology</subject><subject>Mesenteric Artery, Superior - metabolism</subject><subject>Methylene Blue - pharmacology</subject><subject>Muramidase - antagonists & inhibitors</subject><subject>Muramidase - metabolism</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - antagonists & inhibitors</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>omega-N-Methylarginine - pharmacology</subject><subject>Oxadiazoles - pharmacology</subject><subject>Phenylephrine - pharmacology</subject><subject>Prostaglandins - metabolism</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Quinoxalines - pharmacology</subject><subject>Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors</subject><subject>Receptors, Cytoplasmic and Nuclear - metabolism</subject><subject>Sepsis - metabolism</subject><subject>Sepsis - physiopathology</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Soluble Guanylyl Cyclase</subject><subject>Studies</subject><subject>Thionucleotides - pharmacology</subject><subject>Time Factors</subject><subject>Vasoconstrictor Agents - pharmacology</subject><subject>Vasodilation - drug effects</subject><issn>0363-6135</issn><issn>1522-1539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kF2L1DAYhYMo7rj6CwQJXtvZfDYtXsniusKAN-t1SNO3bYZOU5PU3frrzeyMqzdC4L3IeQ6HB6G3lGwplezK7OcBTEhbQoliW0aIeoY2-YcVVPL6OdoQXvKipFxeoFcx7gkhUpX8JbqgFSu5omKD4m6N_td6gA_Y4AO0ziQfsO9whDm6iNNgEp6DbxcLEf800bduNMn5CTcrHtY2-B4mPEPwD64FHF0_mdFNPXYTNvmFBMGZMXfAbMIj-Rq96MwY4c35XqLvN5_vrm-L3bcvX68_7QorGEuFkgxMyQ1rSNW0wpaV7Yg1glrFGWtMI2zVSFlJKohQ1tK2JtAQK0qoFSWcX6L3p968_8cCMem9X0KeFzVjdalkRY8hfgrZ4GMM0Ok5uIMJq6ZEHz3rP571o2d99Jypd-fqpcnW_jJnsTnw8RQYXD_cuwB6Htbo_Oj7Vd8s43gHD-mpmtVCC31LFRN6brtMX_2fftrzD8V_Axkko48</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Mink, Steven N</creator><creator>Kasian, Krika</creator><creator>Santos Martinez, Luis E</creator><creator>Jacobs, Hans</creator><creator>Bose, Ratna</creator><creator>Cheng, Zhao-Qin</creator><creator>Light, R. Bruce</creator><general>American Physiological Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TS</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20080401</creationdate><title>Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation</title><author>Mink, Steven N ; Kasian, Krika ; Santos Martinez, Luis E ; Jacobs, Hans ; Bose, Ratna ; Cheng, Zhao-Qin ; Light, R. Bruce</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-752ea63a2b08bd4c68cf0ca41c7322bab4c8b558514047cc1d90eb0c46e971033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aminoquinolines - pharmacology</topic><topic>Animals</topic><topic>Blood vessels</topic><topic>Carotid Artery, Internal - drug effects</topic><topic>Carotid Artery, Internal - enzymology</topic><topic>Carotid Artery, Internal - metabolism</topic><topic>Catalase - metabolism</topic><topic>Cells</topic><topic>Cyclic GMP - analogs & derivatives</topic><topic>Cyclic GMP - metabolism</topic><topic>Cyclic GMP - pharmacology</topic><topic>Cyclic GMP-Dependent Protein Kinases - antagonists & inhibitors</topic><topic>Cyclic GMP-Dependent Protein Kinases - metabolism</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Dogs</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzymes</topic><topic>Ethanol - pharmacology</topic><topic>Free Radical Scavengers - pharmacology</topic><topic>Guanylate Cyclase - antagonists & inhibitors</topic><topic>Guanylate Cyclase - metabolism</topic><topic>Humans</topic><topic>Hydrogen Peroxide - metabolism</topic><topic>Hydroquinones - pharmacology</topic><topic>In Vitro Techniques</topic><topic>Indomethacin - pharmacology</topic><topic>Mannitol - pharmacology</topic><topic>Mesenteric Artery, Superior - drug effects</topic><topic>Mesenteric Artery, Superior - enzymology</topic><topic>Mesenteric Artery, Superior - metabolism</topic><topic>Methylene Blue - pharmacology</topic><topic>Muramidase - antagonists & inhibitors</topic><topic>Muramidase - metabolism</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - antagonists & inhibitors</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>omega-N-Methylarginine - pharmacology</topic><topic>Oxadiazoles - pharmacology</topic><topic>Phenylephrine - pharmacology</topic><topic>Prostaglandins - metabolism</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Quinoxalines - pharmacology</topic><topic>Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors</topic><topic>Receptors, Cytoplasmic and Nuclear - metabolism</topic><topic>Sepsis - metabolism</topic><topic>Sepsis - physiopathology</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Soluble Guanylyl Cyclase</topic><topic>Studies</topic><topic>Thionucleotides - pharmacology</topic><topic>Time Factors</topic><topic>Vasoconstrictor Agents - pharmacology</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mink, Steven N</creatorcontrib><creatorcontrib>Kasian, Krika</creatorcontrib><creatorcontrib>Santos Martinez, Luis E</creatorcontrib><creatorcontrib>Jacobs, Hans</creatorcontrib><creatorcontrib>Bose, Ratna</creatorcontrib><creatorcontrib>Cheng, Zhao-Qin</creatorcontrib><creatorcontrib>Light, R. Bruce</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>American journal of physiology. Heart and circulatory physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mink, Steven N</au><au>Kasian, Krika</au><au>Santos Martinez, Luis E</au><au>Jacobs, Hans</au><au>Bose, Ratna</au><au>Cheng, Zhao-Qin</au><au>Light, R. Bruce</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation</atitle><jtitle>American journal of physiology. Heart and circulatory physiology</jtitle><addtitle>Am J Physiol Heart Circ Physiol</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>294</volume><issue>4</issue><spage>H1724</spage><epage>H1735</epage><pages>H1724-H1735</pages><issn>0363-6135</issn><eissn>1522-1539</eissn><coden>AJPPDI</coden><abstract>Departments of 1 Medicine, 2 Pharmacology and Therapeutics, and 3 Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada; and 4 Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Submitted 15 September 2007
; accepted in final form 6 February 2008
In septic shock, systemic vasodilation and myocardial depression contribute to the systemic hypotension observed. Both components can be attributed to the effects of mediators that are released as part of the inflammatory response. We previously found that lysozyme (Lzm-S), released from leukocytes, contributed to the myocardial depression that develops in a canine model of septic shock. Lzm-S binds to the endocardial endothelium, resulting in the production of nitric oxide (NO), which, in turn, activates the myocardial soluble guanylate cyclase (sGC) pathway. In the present study, we determined whether Lzm-S might also play a role in the systemic vasodilation that occurs in septic shock. In a phenylephrine-contracted canine carotid artery ring preparation, we found that both canine and human Lzm-S, at concentrations similar to those found in sepsis, produced vasorelaxation. This decrease in force could not be prevented by inhibitors of NO synthase, prostaglandin synthesis, or potassium channel inhibitors and was not dependent on the presence of the vascular endothelium. However, inhibitors of the sGC pathway prevented the vasodilatory activity of Lzm-S. In addition, Aspergillus niger catalase, which breaks down H 2 O 2 , as well as hydroxyl radical scavengers, which included hydroquinone and mannitol, prevented the effect of Lzm-S. Electrochemical sensors corroborated that Lzm-S caused H 2 O 2 release from the carotid artery preparation. In conclusion, these results support the notion that when Lzm-S interacts with the arterial vasculature, this interaction results in the formation of H 2 O 2 , which, in turn, activates the sGC pathway to cause relaxation. Lzm-S may contribute to the vasodilation that occurs in septic shock.
reactive oxygen species; catalase; compound I; hydroxyl radical; septic shock; hypotension
Address for reprint requests and other correspondence: S. N. Mink, Health Sciences Centre, GF-221, 820 Sherbrook St., Winnipeg, Manitoba, Canada R3A 1R9 (e-mail: minksn{at}cc.umanitoba.ca )</abstract><cop>United States</cop><pub>American Physiological Society</pub><pmid>18263714</pmid><doi>10.1152/ajpheart.01072.2007</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0363-6135 |
ispartof | American journal of physiology. Heart and circulatory physiology, 2008-04, Vol.294 (4), p.H1724-H1735 |
issn | 0363-6135 1522-1539 |
language | eng |
recordid | cdi_proquest_journals_229675813 |
source | MEDLINE; American Physiological Society; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Aminoquinolines - pharmacology Animals Blood vessels Carotid Artery, Internal - drug effects Carotid Artery, Internal - enzymology Carotid Artery, Internal - metabolism Catalase - metabolism Cells Cyclic GMP - analogs & derivatives Cyclic GMP - metabolism Cyclic GMP - pharmacology Cyclic GMP-Dependent Protein Kinases - antagonists & inhibitors Cyclic GMP-Dependent Protein Kinases - metabolism Cyclooxygenase Inhibitors - pharmacology Dogs Dose-Response Relationship, Drug Enzyme Inhibitors - pharmacology Enzymes Ethanol - pharmacology Free Radical Scavengers - pharmacology Guanylate Cyclase - antagonists & inhibitors Guanylate Cyclase - metabolism Humans Hydrogen Peroxide - metabolism Hydroquinones - pharmacology In Vitro Techniques Indomethacin - pharmacology Mannitol - pharmacology Mesenteric Artery, Superior - drug effects Mesenteric Artery, Superior - enzymology Mesenteric Artery, Superior - metabolism Methylene Blue - pharmacology Muramidase - antagonists & inhibitors Muramidase - metabolism Nitric oxide Nitric Oxide - metabolism Nitric Oxide Synthase - antagonists & inhibitors Nitric Oxide Synthase - metabolism omega-N-Methylarginine - pharmacology Oxadiazoles - pharmacology Phenylephrine - pharmacology Prostaglandins - metabolism Protein Kinase Inhibitors - pharmacology Quinoxalines - pharmacology Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors Receptors, Cytoplasmic and Nuclear - metabolism Sepsis - metabolism Sepsis - physiopathology Signal transduction Signal Transduction - drug effects Soluble Guanylyl Cyclase Studies Thionucleotides - pharmacology Time Factors Vasoconstrictor Agents - pharmacology Vasodilation - drug effects |
title | Lysozyme, a mediator of sepsis that produces vasodilation by hydrogen peroxide signaling in an arterial preparation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A44%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lysozyme,%20a%20mediator%20of%20sepsis%20that%20produces%20vasodilation%20by%20hydrogen%20peroxide%20signaling%20in%20an%20arterial%20preparation&rft.jtitle=American%20journal%20of%20physiology.%20Heart%20and%20circulatory%20physiology&rft.au=Mink,%20Steven%20N&rft.date=2008-04-01&rft.volume=294&rft.issue=4&rft.spage=H1724&rft.epage=H1735&rft.pages=H1724-H1735&rft.issn=0363-6135&rft.eissn=1522-1539&rft.coden=AJPPDI&rft_id=info:doi/10.1152/ajpheart.01072.2007&rft_dat=%3Cproquest_pubme%3E1460409241%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229675813&rft_id=info:pmid/18263714&rfr_iscdi=true |